DGAP-News: Cinfa Biotech initiates biosimilar strategy with pegfilgrastim candidate to treat neutropenia


DGAP-News: Cinfa Biotech, S.L. / Key word(s): Strategic Company
Decision
Cinfa Biotech initiates biosimilar strategy with pegfilgrastim
candidate to treat neutropenia

08.10.2015 / 09:30

---------------------------------------------------------------------

Press Release

Cinfa Biotech initiates biosimilar strategy with pegfilgrastim candidate to
treat neutropenia

Pamplona, Spain - 8 October 2015 - Cinfa Biotech S.L., the biosimilar
company of Infarco group, today outlined the Company's strategy to develop
and commercialise biosimilar drugs. The Company's first product candidate
is B12019, a biosimilar version of Neulasta(R) (pegfilgrastim), starting
clinical trials in 2015.

B12019 is a granulocyte colony-stimulating factor (G-CSF) receptor agonist
for the treatment of chemotherapy-induced neutropenia. The product
candidate has successfully finalised preclinical development and has an
agreed clinical development program based upon scientific advice received
from the European Medicines Agency (EMA). Furthermore, the manufacturing
process (GMP) has been implemented at commercial scale.

Cinfa Biotech was established by Infarco group, Spain, in 2013. A committed
investment of initially EUR 70 million underlines Infarco's determination
to apply its effective portfolio strategy, as realised by its affiliate
company Laboratorios Cinfa as a leading supplier of quality drugs for the
European market, now to biosimilars. Cinfa Biotech is creating a pipeline
of biosimilars for several indications in oncology and inflammatory
diseases to address the growing need for affordable biologics therapies
based on proven science, quality, safety and efficacy. Product development,
clinical studies, manufacturing and quality control at Cinfa Biotech are
conducted in Europe according to the highest European standards.

Dr. Rüdiger Jankowsky, Managing Director of Cinfa Biotech, said: "Cinfa
Biotech's pipeline and the development of B12019 is driven by a team of
experts in development, manufacturing and commercialization, a team which
has already successfully developed and launched biosimilars in different
markets throughout the world. Cinfa Biotech will be covering the entire
value chain from biosimilar development to commercialization. We are glad
to provide patients, physicians, healthcare providers and business partners
with affordable treatment options and competitive opportunities based on
proven therapies."

Enrique Ordieres, President of Infarco, commented: "The founding of Cinfa
Biotech and our investment in a biosimilar pipeline is following the logic
of our successful business strategy. As demonstrated with Laboratorios
Cinfa, which has become the leading quality supplier for retailing
pharmacies in Spain, now present in over 50 countries, there is an urgent
medical need to ensure that proven, advantageous and affordable medications
are available to all patients. This concept will now be applied to complex
and costly biologic drugs. We are committed to improving patient access to
healthcare solutions and supporting national healthcare systems through
reliable supply of high-quality products. Cinfa Biotech is our answer to
this need."

About Infarco - parent company of Cinfa Biotech
Infarco, the parent company of Cinfa Biotech, holds a portfolio of
pharmaceutical companies. With 50 years' experience, Infarco represents the
successful professional approach of a group of pharmacists to recover the
central role of pharmacists in the pharmaceutical industry. The Company
today employs over 1,200 people and reinvests an average of 90% of its
annual profits in its portfolio companies, thereby driving their
development and innovation. Infarco's first subsidiary, Laboratorios Cinfa,
has become a successful developer and manufacturer and a recognised leader
in the Spanish pharmaceutical market; it is the laboratory with the
strongest presence in Spanish homes. As part of the internationalization
strategy, the company serves markets in currently over 50 countries and is
further expanding.

About Cinfa Biotech
Cinfa Biotech is headquartered in Pamplona, Spain, with offices in Munich,
Germany. The company was founded in 2013 and received an initial investment
of EUR 70 million from Infarco to create a pipeline of biosimilar drugs to
address the growing need for affordable therapies based on proven science,
quality, safety and efficacy. A complete team of experts with decades of
in-depth experience is developing biosimilars for a range of indications.
The commercialisation models will be customised to the needs of partners
and markets. Product development, clinical studies, manufacturing and
quality control at Cinfa Biotech are conducted in Europe according to the
highest European standards.

For Press Enquiries:

MC Services AG
Katja Arnold 
Phone: +49 89 210 228-0 
Email: katja.arnold@mc-services.eu

Shaun Brown
Phone: +44-20-71485998
Email: shaun.brown@mc-services.eu



---------------------------------------------------------------------

08.10.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


400717 08.10.2015
GlobeNewswire